Competition and prices in the Mexican pharmaceutical market

被引：4

作者：

Molina-Salazar, Raul E. ^{[1
]}

Gonzalez-Marin, Eloy ^{[2
]}

Carbajal-de Nova, Carolina ^{[1
]}

机构：

[1] Univ Autonoma Metropolitana Iztapalapa, Dept Econ, Mexico City 09340, DF, Mexico

[2] Univ Autonoma Metropolitana Atzcapotzalco, Mexico City, DF, Mexico

来源：

SALUD PUBLICA DE MEXICO | 2008年 / 50卷

关键词：

essential medicines; prices; patents;

D O I：

10.1590/S0036-36342008001000011

中图分类号：

R1 [预防医学、卫生学];

学科分类号：

1004 ; 120402 ;

摘要：

The forms of market competition define prices.The pharmaceutical market contains submarkets with different levels of competition; on the one hand are the innovating products with patents, and on the other, generic products with or without trade names. Innovating medicines generally have monopolistic prices, but when the patents expire prices drop because of competition from therapeutic alternatives. The trade name makes it easier to maintain monopolistic prices. In Mexico, medicine prices in the private market are high -according to aggregated estimates and prices for specific medicines- which reflect the limitations of pharmaceutical market competition and the power of the trade name. The public segment enjoys competitive prices using the WHO strategy for essential medicines on the basis of the Essential List.

引用

页码：S496 / S503

页数：8

共 50 条

[41] Competition Conditions and Market Power in the Mexican Commercial Banking Market. A Microeconomic Theoretical Approach
Lartigue-Mendoza, Jacques
Azael Ayala-Navarro, Kenneth
Enrique Sauri-Alpuche, Gustavo
[J]. REVISTA FINANZAS Y POLITICA ECONOMICA, 2020, 12 (02): : 367 - 401
[42] A model plant. Mexican market reached the limit in price competition
Martínez, Herbert
[J]. Mari Papel y Corrugado, 2007, 20 (04): : 20 - 22
[43] The effects of drug market regulation on pharmaceutical prices in Europe: Overview and evidence from the market of ace Inhibitors
von der Schulenburg F.
Vandoros S.
Kanavos P.
[J]. Health Economics Review, 1 (1) : 1 - 8
[44] CHANGES IN THE PRICES OF REFERENCE BIOTECHNOLOGY PRODUCTS BY THE PENETRATION OF BIOSIMILARS INTO THE TURKISH PHARMACEUTICAL MARKET
Tuna, E.
Kockaya, G.
[J]. VALUE IN HEALTH, 2015, 18 (07) : A535 - A535
[45] The relative performance of pharmaceutical sector security prices during stock market crashes
Skrepnek, G. H.
Fishman, J. C.
Yancy, M. L.
[J]. VALUE IN HEALTH, 2007, 10 (03) : A36 - A36
[46] A LITERATURE REVIEW OF FACTORS AFFECTING PRICE AND COMPETITION IN THE GLOBAL PHARMACEUTICAL MARKET
Park, Y.
Goto, D.
Yang, K. F.
Downton, K.
Lecomte, P.
Olson, M.
Mullins, C. D.
[J]. VALUE IN HEALTH, 2016, 19 (03) : A265 - A265
[47] Implications of the abolition of pharmaceutical cost regulation for price competition on the OTC market
Stargardt, T.
Schreyoegg, J.
Busse, R.
[J]. GESUNDHEITSWESEN, 2006, 68 (07) : 492 - 492
[48] Dynamics of price competition in Italian pharmaceutical off-patent market
Perna, Serena
Cangini, Agnese
Marini, Roberto
Guerrizio, Maria Alessandra
Da Cas, Roberto
Traversa, Giuseppe
Trotta, Francesco
[J]. FRONTIERS IN MEDICINE, 2022, 9
[49] Regulation and competition in the Taiwanese pharmaceutical market under national health insurance
Liu, Ya-Ming
Yang, Yea-Huei Kao
Hsieh, Chee-Ruey
[J]. JOURNAL OF HEALTH ECONOMICS, 2012, 31 (03) : 471 - 483
[50] PHARMACEUTICAL SUPPLY AND COMPETITION - AN ANALYSIS OF MARKET-STRUCTURE, MARKET BEHAVIOR, AND MARKET RESULTS - GERMAN - ZIEGLER,B
GECK, HM
[J]. JAHRBUCHER FUR NATIONALOKONOMIE UND STATISTIK, 1981, 196 (06): : 575 - 576

← 1 2 3 4 5 →